Long-term prognosis of patients with stroke associated with middle cerebral artery occlusion. Single-centre registration study

Bin Chen, Yufang Sun, Zheng Wei, Yongbo Zhang

Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Submitted: 6 October 2018; Accepted: 9 May 2019
Online publication: 6 August 2019

Arch Med Sci 2022; 18 (5): 1199–1207
DOI: https://doi.org/10.5114/aoms.2019.87129
Copyright © 2019 Termedia & Banach

Abstract

Introduction: Large artery intracranial occlusive disease including middle cerebral artery (MCA) is a major contributor to the incidence of stroke in China. The data on the prognosis of symptomatic atherosclerotic MCA occlusions (MCAO) are limited. We aimed to investigate the related factors of unfavorable outcomes in patients with stroke associated with MCAO.

Material and methods: A total of 119 patients with MCAO symptom were enrolled in this retrospective longitudinal cohort study. All patients met inclusion criteria of cerebral angiography by CT angiography or magnetic resonance angiography. Stroke severity was assessed on admission using the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS).

Results: We showed an average follow-up time of 46.8 months, within which 20 (19.6%) cases died and 14 (13.7%) cases had stroke recurrence. Using mRS as an evaluation index, the patients were divided into an unfavourable outcome group (mRS > 2, 48 cases) and a favourable outcome group (mRS ≤ 2, 54 cases). Logistic regression analysis suggests that age and NIHSS score were independent risk factors for a poor outcome value. Coexisting other cerebral vascular occlusion was an independent risk factor for stroke recurrence. Age was an independent risk factor for death.

Conclusions: The prognosis of patients with MCAO was generally optimistic, with higher survival rate and longer survival time. As compared, elder age and higher NIHSS score both tend to be associated with worse prognosis of survival. MCAO patients with other extracranial or intracranial vascular occlusion have higher risk of recurrent stroke. Death rate increases with age among the MCAO patients.

Key words: middle cerebral artery occlusion, risk factors, prognosis, death, modified Rankin Scale, stroke recurrence.

Introduction

There is a high rate for middle cerebral artery (MCA) lesions to cause stenosis or occlusion in stroke patients. MCA occlusions (MCAO) occur far more than other artery occlusions in ischaemic cerebrovascular diseases and occupy a very important position [1]. A recent study reported a recurrent stroke risk of 12.5% during 12 months among patients with symptoms of middle cerebral artery stenosis or occlusion [2]. The prognosis of patients with large artery occlusion disease of the middle
cerebral artery is relatively poor, with fatality rates up to 80% [3]. Earlier studies on intracranial artery lesions have focused on the risk factors of middle cerebral artery disease, clinical characteristics, imaging, treatment effect comparison, and the short-term prognosis. Long-term prognosis and recurrent stroke rates among patients with MCAO have not attracted much attention [4]. This paper documents a clinical trial of long-term prognosis and risk of recurrent stroke in patients with MCAO in a single centre using CT angiography (CTA) or magnetic resonance angiography (MRA), widely used in the world.

The main purpose of this article is to observe a long-term prognosis of MCAO patients and add information for potential real world studies.

**Material and methods**

**Patient eligibility**

Data were retrospectively collected among patients with middle cerebral ischaemia, including ischaemic stroke and transient ischaemic attack (TIA) diagnosis, evidenced by CTA or MRA in patients from January 2006 to December 2013. The inclusion criteria were: 1) patients hospitalised due to TIA or acute cerebrovascular diseases; 2) cerebral infarction diagnosed according to the criteria established at the Fourth Academic Conference of National Cerebral Vascular Disease in 1995 [5], confirmed by CTA or MRA on admission; 3) head CT scans excluded post-infarction haemorrhage during aggravation of the disease; and 4) patients received standard treatment such as antiplatelet, volume expansion, hypoglycaemic antihyperglycaemic, and neuro-protective therapies. Exclusion criteria are: 1) severe renal or hepatic function deficiency, autoimmune diseases, cancer, haematological diseases, and rheumatic diseases; 2) severe trauma, surgery, or any kind of infection within 2 weeks of disease onset; 3) congenital absence of MCA; and 4) severe stroke: a score higher than 20 points according to the National Institutes of Health Stroke Scale (NIHSS).

Patients took aspirin 300 mg for 3 days and 100 mg daily afterwards. Anti-liopaemic and hypoglycaemic treatment were taken after the diagnosis of hyperlipaemia or hyperglycaemia. Informed consent was obtained from all subjects according to the guidelines of the Ethics Committee.

**Definition of risk factors**

Information on age, sex, hypertension (defined as a history of hypertension, being treated with an antihypertensive agent before admission, or systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg), diabetes mellitus (defined as a history of diabetes mellitus, or being treated for diabetes mellitus or glycosylated haemoglobin ≥ 7% or random venous blood glucose ≥ 11.1 mmol/l and/or fasting blood-glucose ≥ 7.0 mmol/l and/or 2 h after glucose load ≥ 11.1) and hyperlipidaemia (defined as low-density lipoprotein cholesterol 2.6 mmol/l at admission or a history of hyperlipidaemia or receiving lipid-lowering treatment), a history of cerebral ischaemia (including a history of ischaemic stroke and TIA), a history of atrial fibrillation, and a history of coronary heart disease (including a history of myocardial infarction and angina pectoris) were collected. In addition, current smoking (defined as a patient who had smoked continuously ≥ 1 cigarette per day for 6 months), history of alcohol drinking (drinking > 2 units per day on average for men or > 1 unit per day on average for women), and homocysteine (serum level of total homocysteine ≥ 15 μmol/l) status were noted.

Other intracranial arterial occlusions included the intracranial internal carotid artery, anterior cerebral artery, middle cerebral artery, posterior cerebral artery, and basilar artery. Extracranial arterial occlusions included the extracranial internal carotid artery and vertebral artery confirmed by CTA or MRA. The medication compliance (aspirin, clopidogrel, and statins) was followed up by phone or medical records after discharge.

**Follow-up and assessment of end points**

Trained researchers at Beijing Friendship Hospital use standard scripts to collect data at discharge, 6, and 12 months and once a year until 8 years after stroke onset. The enrolled patients filled out questionnaires for the follow-up study. When it was impossible to reach the patients directly or the information provided by the patients was unreliable, the information was obtained from caregivers. Fatality was confirmed either by a death certificate from the citizen registry or the hospital records. End points and safety events included: stroke, TIA, or death.

Disability was measured by the modified Rankin Scale (mRS) score, ranging from 0 to 5, with death rated as 6. Stroke recurrence was defined as sudden functional deterioration in neurological status with a NIHSS recurrence of 4 or higher, or a new focal neurological deficit of vascular origin lasting > 24 h.

**Blood sampling**

Blood samples were collected in polystyrene tubes between 08:30 and 10:00 a.m. by venepuncture of the antecubital vein on the third day after admission. Serum glucose (GLU), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol
(HDL-C), cholesterol (CHOL), uric acid (UA), aspartate transaminase (AST), alanine transaminase (ALT), blood urea nitrogen (BUN), albumin (ALB), or creatinine (Cr) concentrations were measured by enzymatic colourimetric methods with commercially available kits on an AU5821 or 7600 Series Automatic Analyzer (Hitachi, Japan). High-sensitivity C-reactive protein (hs-CRP) in the serum was analysed by an immune turbidimetric assay on a MODULAR-P800 analyser (Roche Diagnostics, Germany) with the manufacturer’s reagents. Fibrinogen (Fbg) and prothrombin temporal activity (PTA) concentrations were measured by freezing method while D-dimer by latex immuno- n turbidimetry with commercially available kits on the CS5100 automatic coagulation analyser. Homocysteine (HCY) in the serum was analysed by a circulating enzymatic with the commercially available kits on an AU5821. White blood cells (WBC) were measured by flow cytology, haemoglobin (Hb) by colorimetric determination, hematocrit (HCT) was obtained by calculation, and blood platelet (PLT) by impedance method with the commercially available kits on an XN-3000 Sysmex. Erythrocyte sedimentation rate (ESR) concentrations were measured by natural settling on VACUETTE SRS100/II, as directed, in the laboratory at Beijing Friendship Hospital of Capital Medical University.

Statistical analysis

Statistical analysis was performed using SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Continuous variables were reported in terms of their means, standard deviations, and Student’s t-test statistics. Numerical data not following normal distributions are characterized by their median (interquartile range (IQR)) values and the Wilcoxon test statistics. Categorical variables were reported as proportions and the χ² test statistics. Univariate and multivariate logistic regression analysis were used to evaluate the relationships between risk factors and the prognosis of MCAO. A favorable clinical outcome was defined as having an mRS score of 2 or lower after follow-up. Statistical significance was set as p < 0.05. This study was approved by the Ethics Committee of Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Results

A total of 119 participating patients from January 2006 to December 2013 were included for the follow-up study with an average of 46.8 months (6–97 months), and a lost rate of 14.28% (17 patients). There were 78 (76%) males and 24 (24%) females, among whom 20 (19.6%) patients died, and 14 (13.7%) patients suffered from recurrent stroke. According to my original data, 3 patients were followed up within 6 months, 8 patients for 1 year, 14 patients for 2 years, 15 patients for 3 years, 10 patients for 4 years, 28 patients for 5 years, 26 patients for 6 years, 9 patients for 7 years, and 6 patients for 8 years or more. Six patients died within the half year, 3 patients died at 1 year, 2 patients died at 2 years, 5 patients died at 3 years, 1 patient died at 4 years, and 2 patients died at 5 years. There was 1 patient with recurrent stroke within the half year, 2 patients at 1 year, 4 patients at 2 years, 1 patient at 3 years, 4 patients at 4 years, 1 patient at 5 years, and 1 patient at 6 years. We did not distinguish between re-current stroke and recurrent TIA.

Modified Rankin Scale as an outcome index of influencing factors

The MCAO patients were divided into two groups according to mRS scoring: favorable group (mRS ≤ 2) and unfavorable group (mRS > 2). Demographic characteristics, and risk and biochemical factors are presented in Table I. Patients of the unfavorable group were older and with more severe stroke, higher hs-CRP, Fbg, D-Dimer, and AST and lower TG level compared to those of the favorable group (median NIHSS score 3 vs. 9, p < 0.01). There were no significant differences in hypertension, hyperlipidaemia, diabetes mellitus, and historical stroke or current smokers between the two groups. Logistic multivariate regression analysis of risk factors indicated that age and NIHSS score were independent predictors of prognosis (statistical results) (Table II).

Factors influencing stroke recurrence

MCAO patients were divided into two groups based on stroke recurrence. Demographic characteristics, and risk and biochemical factors are presented in Table III. Patients with stroke recurrence often had other intracranial or extracranial artery occlusions. Their levels of D-Dimer, CHOL, LDL-C, and UA were lower. There were no significant differences in hypertension, diabetes mellitus, and historical stroke or current smoking between the two groups. Logistic multivariate regression analysis indicates that other coexisting intracranial or extracranial artery occlusions were independent predictors of recurrent stroke (Table IV).

Death as an outcome index of risk factors

The analysis of survival rate using the Life Table Method gives: a 1-year survival rate of 90%, a two-year survival rate of 88%, a 3-year survival rate of 78%, and a 5-year survival rate of 71%. The median survival time was 8 years (Table V, Figure 1).
Table I. Comparisons of favourable and unfavourable outcome associated with MCAO

| Parameter                                      | Unfavourable outcome (mRS > 2) n = 48 | Favourable outcome (mRS ≤ 2) n = 54 | P-value |
|------------------------------------------------|--------------------------------------|------------------------------------|---------|
| Gender (%)                                     | 79.17                                | 74.07                              | 0.545   |
| Age [years]                                    | 67.6 ±10.96                          | 58.56 ±13.37                       | 0.000†  |
| Current smoking (%)                            | 64.58                                | 57.41                              | 0.459   |
| Alcohol (%)                                    | 50.00                                | 37.04                              | 0.187   |
| Hypertension (%)                               | 72.92                                | 74.07                              | 0.895   |
| Diabetes mellitus (%)                          | 37.5                                 | 35.19                              | 0.808   |
| Atrial fibrillation (%)                        | 4.17                                 | 0.00                               | 0.219   |
| History of coronary artery disease (%)         | 27.10                                | 18.52                              | 0.302   |
| History of stroke (%)                          | 20.83                                | 29.63                              | 0.309   |
| Antiplatelet (%)                               | 77.08                                | 64.81                              | 0.175   |
| Statin (%)                                     | 62.50                                | 61.11                              | 0.885   |
| Antiplatelet and statin (%)                    | 58.33                                | 51.85                              | 0.511   |
| With other intracranial artery occlusion (%)   | 16.67                                | 18.52                              | 0.807   |
| NIHSS score at admission                      | 9 (4–13)                             | 3 (1–12)                           | 0.002‡  |
| ESR [mm/h]                                     | 28.23 ±25.63                         | 19.15 ±14.87                       | 0.111   |
| hs-CRP [mg/dl]                                 | 4.56 (2.15–11.13)                    | 2.12 (1.00–4.15)                   | 0.002‡  |
| WBC [×10^9/l]                                  | 7.375 (5.79–8.53)                    | 6.77 (5.85–8.70)                   | 0.447   |
| Hb [mg/l]                                      | 137.13 ±18.62                        | 139.40 ±14.80                      | 0.414   |
| HCT (%)                                        | 40.53 ±5.19                          | 40.95 ±4.44                        | 0.669   |
| PLT [×10^9/l]                                   | 228.30 ±74.46                        | 225.45 ±56.56                      | 0.829   |
| HCY [μmol/l]                                   | 19.60 (13.70–26.90)                  | 16.70 (13.75–22.00)                | 0.217   |
| CHOL [mmol/l]                                  | 4.51 ±1.37                           | 4.75 ±1.33                         | 0.384   |
| TG [mmol/l]                                    | 1.36 ±0.58                           | 1.89 ±1.25                         | 0.008†  |
| HDL-C [mmol/l]                                 | 0.99 (0.81–1.24)                     | 0.93 (0.71–1.07)                   | 0.366   |
| LDL-C [mmol/l]                                 | 2.65 ±0.86                           | 2.80 ±0.73                         | 0.361   |
| GLU [mmol/l]                                   | 5.53 (4.89–6.48)                     | 5.62 (4.56–7.57)                   | 0.733   |
| ALT [U/l]                                      | 22.70 ±17.04                         | 18.85 ±10.84                       | 0.173   |
| AST [U/l]                                      | 21.00 (17.00–31.00)                  | 16.50 (14.00–20.25)                | 0.000*  |
| ALB [g/l]                                      | 37.45 ±3.92                          | 38.32 ±3.66                        | 0.279   |
| UA [μmol/l]                                    | 256.51 ±80.46                        | 272.57 ±112.71                     | 0.420   |
| Cr [μmol/l]                                    | 79.00 (67.00–89.00)                  | 83.00 (73.00–90.50)                | 0.423   |
| BUN [mmol/l]                                   | 4.97 (3.77–5.88)                     | 4.40 (3.65–5.31)                   | 0.053   |
| Fbg [g/l]                                      | 4.68 (3.35–15.00)                    | 3.32 (2.38–4.68)                   | 0.001†  |
| D-dimer [mg/l]                                 | 0.50 (0.17–1.50)                     | 0.38 (0.10–0.68)                   | 0.039*  |
| PTA (%)                                        | 70.67 ±25.87                         | 73.10 ±31.47                       | 0.090   |

Data are shown as mean ± standard deviation (SD), frequency as a number (%). *p < 0.05 for differences from the other group, †p < 0.01 for differences from other group. MCAO – middle cerebral artery occlusions, mRS – modified Rankin scale, NIHSS – the National Institutes of Health Stroke Scale, ESR – erythrocyte sedimentation rate, hs-CRP – C-reactive protein, WBC – white blood cells, Hb – haemoglobin, HCT – haematocrit, PLT – blood platelet, HCY – homocysteine, CHOL – cholesterol, TG – triglyceride, HDL-C – high-density lipoprotein cholesterol, LDL-C – low-density lipoprotein cholesterol, GLU – serum glucose, ALT – alanine transaminase, AST – aspartate transaminase, ALB – albumin, UA – uric acid, Cr – creatinine, BUN – blood urea nitrogen, Fbg – fibrinogen, PTA – prothrombin temporal activity.
Based on survival and death information, the MCAO patients at the end point of the study were divided accordingly with the corresponding demographic characteristics, and risk and biochemical factors shown in Table VI. Significant risk factors were identified in patients with a history of coronary heart disease, and/or HCY. High serum levels of hs-CRP, ESR, Fbg, D-dimer, AST, and BUN were detected in these patients, as well as lower proportion of alcohol consumption history, TG, and ALB levels. There were no significant differences in hypertension, hyperlipidaemia, diabetes mellitus, NIHSS and historical stroke or current smoking status between the two groups. Logistic multivariate re-gression analysis revealed that the age was an independent predictor of death outcome, and a drinking history was a protective factor of death (statistical results) (Table VII).

Discussion

Stroke has become one of the most common causes of death in China [6, 7]. The current study investigated long-term outcomes, mortality rate, and influence factors of MCAO patients. We also attempted to identify potential biomarkers of MCAO as partial evidences of prognosis for MCAO.

Our analysis suggested that the age is an independent predictor of death outcome. The risk of death increased with age, and the clinical prognosis of the surviving patients worsened with higher NIHSS score. In our results, factors including ESR, h-CRP, HCY, Fbg, D-dimer, AST, BUN, and history of coronary heart disease were not independent predictors. Age could increase the risk of death among patients with cerebrovascular diseases and affect the functional prognosis among the surviving patients. Zemtsovskaia et al. [8] also found that aging showed the strongest association with cardiovascular (CV) risk levels, indicative of increased arterial stiffness. The increase in NIHSS score was not positively correlated with the risk of death, but with the rate of disability. In other words, as long as the MCAO patients received prompt and effective treatment during the acute stage of cerebral infarction, the risk of death did not vary with the severity of cerebrovascular disease. We have shown that age and NIHSS affect prognosis, which is consistent with the findings from earlier studies [9–13]. Tian et al. [14] investigated 232 MCAO patients with the average follow-up time of 17.65 months, and stroke recurrence or death as the end point event (15.09% incidence of endpoint events, resulting in annual rate of 10.26%). It was concluded that patients with symptomatic M1-segment occlusion of the middle cerebral artery had a good long-term prognosis. The factors influencing the prognosis of patients are gender, diabetes mellitus and concomitant intracranial arterial disease. Similar to the rate of endpoint events in this study, the risk of recurrent stroke and death rate of the MCAO patients were 13.7% and 19.6% in our cohort. The analysis of the recurrence of stroke as an independent endpoint event in this study suggested that patients with other intracranial or extracranial vascular occlusion had higher risk of recurrence of stroke, consistent with the previous studies.

C-reactive protein, an indicator of inflammation and a marker of atherosclerosis [15–17], is associated with ischaemic attacks among patients with ischaemic stroke [18–23]. In a controlled case study of 600 ischaemic stroke patients and 600 matched controls, serum CRP levels were significantly higher for all ischaemic subtypes than controls, both in the acute phase and at 3-month follow-up [24]. Rost et al. found that elevated serum CRP levels could be used for predicting the risk of ischaemic stroke in elderly patients [19]. Xie et al. [25] found that ischaemic stroke patients with ICAO had significantly higher hs-CRP levels than controls, further confirming hs-CRP being a sensitive inflammation marker for the presence of ICAO in ischaemic stroke patients. In this study, we found that h-CRP in MCAO patients with functionally poor prognosis or death was significantly increased, but there was no significant difference in h-CRP between the MCAO recurrence group and non-recurrence group.

Oh et al. [26] followed 141 patients with symptomatic isolated middle cerebral artery lesions (including more than 50% stenosis and occlusion) for long-term prognosis (mean follow-up time was 27.7 months) and found that diabetes is an independent risk factor for predicting stroke recurrence and mortality. There was no difference in mortality and recurrence rate between MCAO

| Factor          | B   | SE  | Wald | Sig. | Exp (B) | OR (95% CI) |
|-----------------|-----|-----|------|------|---------|-------------|
| NIHSS score     | 0.168 | 0.060 | 7.919 | 0.005 | 1.184 | 1.052–1.331 |
| Age [years]     | 0.056 | 0.023 | 5.753 | 0.016 | 1.058 | 1.010–1.108 |
| Constant        | –4.632 | 1.706 | 7.376 | 0.007 | 0.0010 |             |

\( p < 0.05 \) considered to be significant. MCAO – middle cerebral artery occlusions, NIHSS – the National Institutes of Health Stroke Scale, SE – standard error, OR – odds ratio.

Table II. Multivariate logistic regression results for independent predictors of an unfavourable outcomes associated with MCAO.
### Table III. Comparisons between patients with or without recurrent stroke

| Parameter                              | With stroke recurrence (n = 14) | Without stroke recurrence (n = 88) | P-value |
|----------------------------------------|---------------------------------|-----------------------------------|---------|
| Gender (%)                             | 64.29                           | 78.41                             | 0.247   |
| Age [years]                            | 67.6 ±10.96                     | 58.56 ±13.37                      | 0.000†  |
| Current smoking (%)                    | 71.43                           | 59.09                             | 0.560   |
| Alcohol (%)                            | 35.71                           | 44.32                             | 0.546   |
| Hypertension (%)                       | 71.43                           | 73.86                             | 1.000   |
| Diabetes mellitus (%)                  | 42.86                           | 35.23                             | 0.581   |
| Atrial fibrillation (%)                | 0.00                            | 2.27                              | 1.000   |
| History of coronary artery disease (%) | 21.43                           | 21.59                             | 1.000   |
| History of stroke (%)                  | 7.14                            | 28.41                             | 0.113   |
| Antiplatelet (%)                       | 64.29                           | 69.32                             | 0.834   |
| Statin (%)                             | 62.50                           | 61.36                             | 0.885   |
| Antiplatelet and statin (%)            | 50.00                           | 55.68                             | 0.691   |
| With other intracranial artery occlusion (%) | 42.86                           | 13.64                             | 0.008†  |
| NIHSS score at admission               | 7.36 ±5.26                      | 6.89 ±5.50                        | 0.766   |
| ESR [mm/h]                             | 19.44 ±13.65                    | 24.84 ±22.79                      | 0.496   |
| hs-CRP [mg/dl]                         | 2.96 (1.56–5.66)                | 3.60 (1.50–9.90)                  | 0.736   |
| WBC [*10^9/l]                          | 7.01 (5.71–8.36)                | 6.97 (5.85–8.70)                  | 0.810   |
| Hb [mg/l]                              | 140.64 ±11.80                   | 137.96 ±17.32                     | 0.579   |
| HCT (%)                                | 41.25 ±2.91                     | 40.67 ±5.03                       | 0.547   |
| PLT [*10^9/l]                          | 229.00 ±64.59                   | 226.41 ±65.62                     | 0.891   |
| HCY [μmol/l]                           | 16.46 ±6.81                     | 20.43 ±10.14                      | 0.233   |
| CHOL [mmol/l]                          | 3.83 ±1.38                      | 4.77 ±1.30                        | 0.015*$ |
| TG [mmol/l]                            | 1.38 (1.03–1.61)                | 1.39 (1.11–1.99)                  | 0.619   |
| HDL-C [mmol/l]                         | 1.14 (0.73–5.09)                | 0.93 (0.80–1.14)                  | 0.116   |
| LDL-C [mmol/l]                         | 2.29 ±0.81                      | 2.81 ±0.77                        | 0.024*$ |
| GLU [mmol/l]                           | 4.60 ±3.31                      | 6.06 ±2.33                        | 0.134   |
| ALT [U/l]                              | 14.50 (10.00–24.00)             | 17.00 (12.00–26.00)               | 0.482   |
| AST [U/l]                              | 19.00 (14.75–24.50)             | 19.00 (15.00–25.00)               | 0.704   |
| ALB [g/l]                              | 39.02 ±2.96                     | 37.66 ±3.92                       | 0.219   |
| UA [μmol/l]                            | 211.81 ±52.74                   | 273.69 ±101.90                    | 0.029*$ |
| BUN [mmol/l]                           | 4.31 ±1.42                      | 4.84 ±1.66                        | 0.266   |
| Cr [μmol/l]                            | 78.07 ±17.26                    | 82.80 ±25.47                      | 0.639   |
| Fbg [g/l]                              | 4.86 (3.70–10.00)               | 3.70 (2.69–5.78)                  | 0.160   |
| D-dimer [mg/l]                         | 0.13 (0.07–0.77)                | 0.43 (0.15–1.00)                  | 0.043*$ |
| PTA (%)                                | 64.54 ±33.58                    | 73.00 ±28.31                      | 0.365   |

Data are shown as mean ±SD, frequency as a number (%). *p < 0.05 for differences from without stroke recurrence, †p ≤ 0.001 for differences from without stroke recurrence. Abbreviations: see Table I.
Table IV. Multivariate logistic regression results for patients with or without recurrent stroke

| Factor                                                       | B   | SE  | Wald | Sig.  | Exp (B) | OR (95% CI) |
|--------------------------------------------------------------|-----|-----|------|-------|---------|-------------|
| With other intracranial or extracranial artery occlusion (%) | 2.218 | 0.750 | 8.751 | 0.003* | 9.187   | 2.114–39.935 |
| Constant                                                     | -2.506 | 0.520 | 23.215 | 0.000' |         |             |

*p < 0.05 considered to be significant, †p ≤ 0.001 for differences from without stroke recurrence. Abbreviations: see Table II.

Table V. Survival rate analysis

| Interval start time    | 0 month | 6 months | 1 year | 2 years | 3 years | 4 years | 5 years | 6 years | 7 years | 8 years |
|------------------------|---------|----------|--------|---------|---------|---------|---------|---------|---------|---------|
| No. entering interval  | 102     | 97       | 88     | 72      | 57      | 46      | 28      | 10      | 5       | 1       |
| Cumulative proportion surviving at end of interval (%)      | 95      | 94       | 90     | 88      | 78      | 78      | 71      | 71      | 71      |

In conclusion, our finding show that most cases of middle cerebral artery occlusion are associated with better prognosis, especially when associated with lower age at onset and less severe NIHSS score. Recurrent strokes in patients with middle cerebral artery occlusion are linked to the presence of other intra- or extracranial atherosclerotic occlusions.

Acknowledgments

Funding for this study was provided by grants from the National Natural Science Foundation of China (No. 81371355 and No. 81671191 to YBZ, and No. 81500989 to BC). We thank Dr Jingfeng Wang PhD, GT, Atlanta, GA for comments that...
Table VI. Comparison between the death and survival groups associated with MCAO

| Parameter | The death group (n = 20) | The survival group (n = 82) | P-value |
|-----------|-------------------------|-----------------------------|---------|
| Gender (%) | 90.00 | 73.17 | 0.195 |
| Age [years] | 74.15 ±5.36 | 59.94 ±12.89 | 0.000† |
| Antiplatelet therapy (%) | 75.00 | 69.51 | 0.834 |
| Statins (%) | 65.00 | 60.98 | 0.740 |
| Antiplatelet and statin (%) | 60.00 | 52.44 | 0.543 |
| Current smoking (%) | 80.00 | 56.10 | 0.088 |
| Alcohol (%) | 35.00 | 62.20 | 0.028* |
| Hypertension (%) | 65.00 | 75.6 | 0.335 |
| Diabetes mellitus (%) | 55.00 | 31.70 | 0.052 |
| Atrial fibrillation (%) | 0.00 | 2.44 | 0.645 |
| History of coronary artery disease (%) | 45.00 | 15.85 | 0.004† |
| History of stroke (%) | 25.00 | 25.61 | 0.955 |
| Coexisting other intracranial or extracranial artery occlusion (%) | 10.00 | 19.51 | 0.501 |
| NIHSS | 6.00 (2.25–11.75) | 5.5 (2.00–12.00) | 0.852 |
| ESR [mm/h] | 37.60 ±30.42 | 19.26 ±15.39 | 0.039† |
| h-CRP [mg/dl] | 7.00 (2.55–11.35) | 2.73 (1.18–8.91) | 0.031† |
| WBC [×10^9/l] | 9.14 ±6.42 | 7.48 ±2.50 | 0.271 |
| HB [mg/l] | 132.20 ±19.47 | 139.90 ±15.59 | 0.064 |
| HCT (%) | 39.81 ±1.19 | 40.99 ±0.52 | 0.326 |
| PLT [×10^9/l] | 244.60 ±94.26 | 222.26 ±55.38 | 0.320 |
| PTA (%) | 69.77 ±24.60 | 72.46 ±29.87 | 0.737 |
| Fbg [g/l] | 8.90 (4.49–27.75) | 3.46 (2.56–5.33) | 0.000† |
| D-dimer [mg/l] | 0.49 (0.20–2.00) | 0.38 (0.13–1.00) | 0.031† |
| HCY [μmol/l] | 25.00 (14.20–31.60) | 17.40 (13.63–23.00) | 0.037† |
| TG [mmol/l] | 1.12 (0.77–1.31) | 1.45 (1.15–2.01) | 0.001† |
| CHOL [mmol/l] | 4.25 ±1.09 | 4.73 ±1.39 | 0.160 |
| LDL-C [mmol/l] | 2.53 ±0.80 | 2.78 ±0.79 | 0.227 |
| HDL-C [mmol/l] | 1.02 (0.74–1.20) | 0.93 (0.79–1.19) | 0.776 |
| GLU [mmol/l] | 5.60 ±2.55 | 5.92 ±2.52 | 0.619 |
| ALT [U/l] | 20.50 (11.25–28.50) | 16.00 (12.00–24.50) | 0.5681 |
| AST [U/l] | 22.50 (18.25–29.75) | 18.00, (15.00–21.50) | 0.008† |
| ALB [g/l] | 35.78 ±3.70 | 38.46 ±3.64 | 0.005† |
| Cr [μmol/l] | 103.00 ±53.72 | 78.92 ±14.81 | 0.282 |
| BUN [mmol/l] | 5.44 ±2.44 | 4.60 ±1.33 | 0.038† |
| UA [μmol/l] | 257.62 ±97.83 | 266.76 ±99.45 | 0.718 |

Data are shown as mean ± SD, frequency as a number (%). *p < 0.05 for differences from control subjects, †p < 0.01 for differences from control subjects. Abbreviation: see Table I.

Table VII. Multivariate regression analysis of MCAO patients death group and survival group

| Factor | B | SE | Wald | P-value | Exp (B) | OR (95% CI) |
|--------|---|----|------|---------|--------|------------|
| Age | 0.142 | 0.045 | 9.818 | 0.002 | 1.153 | 1.055–1.260 |
| Alcohol | −2.003 | 0.763 | 6.884 | 0.009 | 0.135 | 0.030–0.602 |
| Constant | −7.943 | 2.956 | 7.222 | 0.007 | 0.000 | 0.000 |

Abbreviation: see Table II.
greatly improved the manuscript. We also thank the two anonymous reviewers for their critical and constructive comments.

Conflict of interest

The authors declare no conflict of interest.

References

1. Klein IF, Labreuche J, Lavallee PC, et al. Is moderate atherosclerotic stenosis in the middle cerebral artery a cause of or a coincidental finding in ischemic stroke? Stroke 2010; 41: 2340-4.
2. Kern R, Steinke W, Daffertshofer M, Prager R, Hennerici M. Stroke recurrences in patients with symptomatic vs asymptomatic middle cerebral artery disease. Neurology 2005; 65: 859-64.
3. Hofmeijer J, Kappelle LJ, Algra A, et al. Surgical decompression for space-occupying cerebral infarction (the Hemicraniectomy After Middle Cerebral Artery infarction with Life-threatening Edema Trial [HAMLET]): a multicentre, open, randomised trial. Lancet Neurol 2009; 8: 326-33.
4. Tanaka M, Shimosegawa E, Kajimoto K, et al. Chronic middle cerebral artery occlusion: a hemodynamic and metabolic study with positron-emission tomography. AJNR Am J Neuroradiol 2008; 29: 1956-60.
5. Chen QT. Scoring standard of clinical neurological deficit in patients with stroke (1995). Chin J Neurol 1996; 29: 381-3.
6. Liu L, Wang D, Kong S, Wang Y. Stroke and stroke care in China: huge burden, significant workload, and a national priority. Stroke 2011; 42: 3651-4.
7. Yang G, Wang Y, Zeng Y, et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2013; 381: 1987-2015.
8. Zemtsovskaia G, Abina J, Meigas K, Pilt K, Viigimaa M. Pulse wave velocity and its gender-related associations with cardiovascular risk factors in a high cardiovascular risk population. Arch Med Sci Atheroscler Dis 2018; 3: e99-e105.
9. Sun W, Li G, Zeng X, et al. Clinical and imaging characteristics of cerebral infarction in patients with non-valvular atrial fibrillation combined with cerebral artery stenosis. J Atheroscler Thromb 2018; 25: 720-32.
10. Zemtsovskaia G, Abina J, Meigas K, Pilt K, Viigimaa M. Pulse wave velocity and its gender-related associations with cardiovascular risk factors in a high cardiovascular risk population. Arch Med Sci Atheroscler Dis 2018; 3: e99-e105.
11. Mokin M, Primiani CT, Ren Z, et al. Endovascular treatment of middle cerebral artery M2 occlusion strokes: clinical and procedural predictors of outcomes. Neurosurgery 2017; 81: 795-802.
12. Zaidi SF, Aghaebrahim A, Urra X, et al. Futility of reperfusion and predicted therapeutic benefits after successful endovascular treatment according to initial stroke severity. BMC Neurol 2019; 19: 11.
13. Borggrefe J, Glück B, Maus V, et al. Clinical outcome after mechanical thrombectomy in patients with diabetes with major ischemic stroke of the anterior circulation. World Neurosurg 2018; 120: 212-20.
14. Tian L, Yue X, Xi G, et al. Multiple intracranial arterial stenosis influences the long-term prognosis of symptomatic middle cerebral artery occlusion. BMC Neurology 2015; 15: 68.
15. Liu M, Wu B, Wang WZ, Lee LM, Zhang SH, Kong LZ. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol 2007; 6: 456-64.
16. Kianoush S, Bittencourt MS, Lotufo PA, et al. Association between smoking and serum GlycA and high-sensitivity C-reactive protein levels: the Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Am Heart Assoc 2017; 6: 006545.
17. Yousef O, Mohanty BD, Martin SS, et al. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link? J Am Coll Cardiol 2013; 62: 397-408.
18. Fonseca FA, Izac MC. High-sensitivity C-reactive protein and cardiovascular disease across countries and ethnicities. Clinics (Sao Paulo) 2016; 71: 235-42.
19. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001; 32: 2575-9.
20. Jiménez MC, Rexrode KM, Glynn RJ, Ridker PM, Gaziano JM, Sesso HD. Association between high-sensitivity C-reactive protein and total stroke by hypertensive status among men. J Am Heart Assoc 2015; 4: e002073.
21. Kotur-Stevuljevic J, Bogavac-Stanojevic N, Jelic-Ivanovic Z, et al. Oxidative stress and paraoxonase 1 status in acute ischemic stroke patients. Atherosclerosis. 2015; 241: 192-8.
22. Wong KS, Ng PW, Tang A, Liu R, Yeung V, Tomlinson B. Prevalence of asymptomatic intracranial atherosclerosis in high-risk patients. Neurology. 2007; 68: 2035-8.
23. Schillinger M, Exner M, Mekusch W, et al. Inflammation and Carotid Artery: Risk for Atherosclerosis Study (ICAR-AS). Circulation 2005; 111: 2203-9.
24. Puz P, Lasek-Bal A, Ziaja D, Kazibutowska Z, Ziaja K. Inflammatory markers in patients with internal carotid artery stenosis. Arch Med Sci Atheroscler Dis 2008; 4: 281-6.
25. Xie D, Hu D, Zhang Q, Sun Y, Li J, Zhang Y. Increased high-sensitivity C-reactive protein, erythrocyte sedimentation rate and lactic acid in stroke patients with internal carotid artery occlusion. Arch Med Sci 2016; 12: 546-51.
26. Oh MS, Yu KH, Chu MK, et al. Long-term prognosis of symptomatic isolated middle cerebral artery disease in Korean stroke patients. BMC Neurology 2011; 11: 138.
27. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths. Lancet 2007; 370: 1829-39.
28. Kang BS, Kwon HM, Ryu WS, et al. Prognosis of symptomatic and asymptomatic middle cerebral artery occlusion. Cerebrovasc Dis 2008; 26: 489-93.